Cargando…

Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo

BACKGROUND: The modest benefits of gemcitabine (dFdC) therapy in patients with pancreatic ductal adenocarcinoma (PDAC) are well documented, with drug delivery and metabolic lability cited as important contributing factors. We have used a mouse model of PDAC: KRAS(G12D); p53(R172H); pdx-Cre (KPC) tha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bapiro, T E, Frese, K K, Courtin, A, Bramhall, J L, Madhu, B, Cook, N, Neesse, A, Griffiths, J R, Tuveson, D A, Jodrell, D I, Richards, F M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102943/ https://www.ncbi.nlm.nih.gov/pubmed/24874484 http://dx.doi.org/10.1038/bjc.2014.288

Ejemplares similares

Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells
por: Lin, Y, et al.
Publicado: (2012)

Anti-Tumour Efficacy of Capecitabine in a Genetically Engineered Mouse Model of Pancreatic Cancer
por: Courtin, Aurélie, et al.
Publicado: (2013)

A novel method for quantification of gemcitabine and its metabolites 2′,2′-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC–MS/MS: comparison with (19)F NMR spectroscopy
por: Bapiro, Tashinga E., et al.
Publicado: (2011)

Purinergic regulation of angiogenesis by human breast carcinoma-secreted nucleoside diphosphate kinase
por: Rumjahn, S M, et al.
Publicado: (2007)

Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells
por: Nakano, Y, et al.
Publicado: (2007)

The role of apoptotic cell death in the radiosensitising effect of gemcitabine
por: Pauwels, B, et al.
Publicado: (2009)

Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma
por: Cham, K K Y, et al.
Publicado: (2010)

Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms
por: Gujar, S A, et al.
Publicado: (2014)

SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice
por: Neesse, Albrecht, et al.
Publicado: (2014)

In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients
por: Mey, V, et al.
Publicado: (2006)

Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer
por: Granata, A, et al.
Publicado: (2014)

Preclinical relevance of dosing time for the therapeutic index of gemcitabine–cisplatin
por: Li, X M, et al.
Publicado: (2005)

Curcumin–cyclodextrin complexes potentiate gemcitabine effects in an orthotopic mouse model of lung cancer
por: Rocks, N, et al.
Publicado: (2012)

Cyclopentenyl cytosine increases gemcitabine radiosensitisation in human pancreatic cancer cells
por: van Bree, C, et al.
Publicado: (2008)

Expression of V(1A) and GRP receptors leads to cellular transformation and increased sensitivity to substance-P analogue-induced growth inhibition
por: MacKinnon, A C, et al.
Publicado: (2005)

CXCL12–CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy
por: Singh, S, et al.
Publicado: (2010)

Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells
por: Bocci, G, et al.
Publicado: (2005)

Gemcitabine–oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed
por: Lee, J-L, et al.
Publicado: (2014)

Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK
por: Patel, Girijesh Kumar, et al.
Publicado: (2017)

Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study
por: Gunelli, R, et al.
Publicado: (2007)

Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1
por: Akashi, Y, et al.
Publicado: (2014)

Tumour growth and resistance to gemcitabine of pancreatic cancer cells are decreased by AP-2α overexpression
por: Jonckheere, N, et al.
Publicado: (2009)

Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer
por: Hessmann, E, et al.
Publicado: (2018)

Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma
por: Vincenzi, Bruno, et al.
Publicado: (2017)

Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib
por: Courtin, Aurelie, et al.
Publicado: (2016)

Fluorescence-guided surgical sampling of glioblastoma identifies phenotypically distinct tumour-initiating cell populations in the tumour mass and margin
por: Piccirillo, S G M, et al.
Publicado: (2012)

Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile
por: Giovannetti, E, et al.
Publicado: (2005)

Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma
por: Campbell, L, et al.
Publicado: (2008)

Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors
por: Kaymakcalan, M D, et al.
Publicado: (2013)

Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy
por: Griffiths, R W, et al.
Publicado: (2005)

Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations
por: Bramley, M, et al.
Publicado: (2006)

Expression and DNA methylation of TNF, IFNG and FOXP3 in colorectal cancer and their prognostic significance
por: Ganapathi, S K, et al.
Publicado: (2014)

[(18)F]2-Fluoro-2-deoxy-D-glucose incorporation by AGS gastric adenocarcinoma cells in vitro during response to epirubicin, cisplatin and 5-fluorouracil
por: Suttie, S A, et al.
Publicado: (2007)

Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells
por: Byron, S A, et al.
Publicado: (2006)

Characterisation and internalisation of recombinant humanised HMFG-1 antibodies against MUC1
por: Pericleous, L M, et al.
Publicado: (2005)

Variation in dermcidin expression in a range of primary human tumours and in hypoxic/oxidatively stressed human cell lines
por: Stewart, G D, et al.
Publicado: (2008)

An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells
por: Yashiro, M, et al.
Publicado: (2011)

p28, A first in class peptide inhibitor of cop1 binding to p53
por: Yamada, T, et al.
Publicado: (2013)

HER2 expression as a potential marker for response to therapy targeted to the EGFR
por: Emlet, D R, et al.
Publicado: (2006)

Phellinus linteus suppresses growth, angiogenesis and invasive behaviour of breast cancer cells through the inhibition of AKT signalling
por: Sliva, D, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_do9m0tqb18ts3pae6gqb8pfhut